89508-48-5

Upstream product

• 204394-76-3 2-(pyridin-4-yl)pyrimidine-4,6-diol 
• 1193-21-1 4,6-dichloropyrimidine 
• 1120-87-2 4-bromopyridin 
• 6345-27-3 4-amidinopyridine hydrochloride 

Relevant academic research and scientific papers

Nitrogen heterocyclic compound, display panel and display device

The invention belongs to the technical field of OLEDs and provides a nitrogen heterocyclic compound. The structure of the nitrogen heterocyclic compound is shown as a chemical formula 1; wherein X1 and X2 each independently represent C or N, and at least one of X1 and X2 is an N atom; X3 to X7 each independently represent N or -CRa, and 1 to 4 of X3 to X7 are N atoms; Ra is selected from hydrogen,deuterium, a Cl-C20 alkyl group, a Cl-C20 alkoxy group, a Cl-C20 thioalkyl group, a C6-C30 aryl group, or a C3-C30 heteroaryl group; Ra independently exists or forms an aliphatic ring, an aromatic ring or a heteroaromatic ring with an adjacent carbon atom; Ar1 and Ar2 are each independently selected from the group consisting of a C6-C30 aryl group and a C3-C30 heteroaryl group; L1 and L2 are independently a single bond, a C6-C30 arylene group, or a C3-C30 heteroarylene group. When the nitrogen heterocyclic compound provided by the invention is used as a cap layer material of an OLED, a relatively high refractive index can be obtained, the external quantum efficiency of an organic light-emitting device can be effectively improved, and the nitrogen heterocyclic compound has a very small extinction coefficient in a blue light region (400-450 nm), hardly absorbs blue light, and is beneficial to improving the light-emitting efficiency. The invention further provides a display panel and a display device.

PREPARATION AND USES OF PYRIMIDINONE DERIVATIVES

The present invention relates to compounds of formula (I), and salts and solvates thereof, that function as inhibitors of cell division cycle 7 (Cdc7) kinase enzyme activity: (Formula (I)) wherein X, R1, R2, and n are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which Cdc7 kinase activity is implicated.

Trisubstituted Pyrimidines as Efficacious and Fast-Acting Antimalarials

In this paper we describe the optimization of a phenotypic hit against Plasmodium falciparum, based on a trisubstituted pyrimidine scaffold. This led to compounds with good pharmacokinetics and oral activity in a P. berghei mouse model of malaria. The most promising compound (13) showed a reduction in parasitemia of 96% when dosed at 30 mg/kg orally once a day for 4 days in the P. berghei mouse model of malaria. It also demonstrated a rapid rate of clearance of the erythrocytic stage of P. falciparum in the SCID mouse model with an ED90 of 11.7 mg/kg when dosed orally. Unfortunately, the compound is a potent inhibitor of cytochrome P450 enzymes, probably due to a 4-pyridyl substituent. Nevertheless, this is a lead molecule with a potentially useful antimalarial profile, which could either be further optimized or be used for target hunting.

HETEROARYL COMPOUNDS

This invention relates to compounds of formula (I) their compositions and methods of use thereof. The compounds (and compositions) are useful in modulating IL-12 production and processes mediated by IL-12.

Pyrimidine derivatives as IL-8 receptor antagonists

Compounds containing the pyrimidine nucleus and their use to treat diseases and conditions related to inappropriate Interleukin-8 receptor activity are disclosed. The compounds are of the formula I In these compounds, Q is preferably unsubstituted and substituted heterocyclyl; U is usually hydrogen or fluorine; and V is preferably hydrogen, halogen, alkyl, —O—alkyl or —S-alkyl. A representative example is: